BioAge Labs, Inc. has dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept clinical trial evaluating BGE-102, an oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE